Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Sinotherapeutics Inc. is currently managing 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This prosecution is being handled by 1 distinct examiner, PARK, HAEJIN S, and is located within a distinct art unit. As the busiest examiner, she is responsible for the pending office action, which accounts for the company's entire current workload before the patent office.
The concentration of a pending office action under an examiner and art unit indicates a highly focused prosecution effort. In the Biotechnology & Pharmaceuticals field, where patent applications can be extensive, this focus suggests the company is currently prioritizing the advancement of a specific asset or technology. The pending office action serves as the sole point of active dialogue between the company and the examiner.
Because the company has the examiner and art unit involved, the prosecution strategy is streamlined. The outcome of the pending office action is the primary factor in the company's current patenting progress. Practitioners can focus their analysis on the specific requirements of the art unit and the individual tendencies of PARK, HAEJIN S to navigate this pending matter.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PARK, HAEJIN S | 1 | 55.0% | +38.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18712989 | DAROLUTAMIDE PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | PARK, HAEJIN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18712989 | DAROLUTAMIDE PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | PARK, HAEJIN S | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18712989 | DAROLUTAMIDE PHARMACEUTICAL COMPOSITION, PREPARATION METHOD THEREFOR AND USE THEREOF | PARK, HAEJIN S | 1614 | §102§103§112 | Non-Final OA | — | Pending | May 23, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial